文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

澳大利亚注射吸毒者初始犹豫后COVID-19疫苗接种率较高

High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
PubMed 文献 · Vaccine · 2024-03-22

2022年6-7月在澳大利亚首都城市调查868名定期注射吸毒者,84.1%至少接种一剂COVID-19疫苗,79.6%接种至少两剂,46.1%接种至少三剂。接种率低于澳大利亚一般人群(患病率比0.82,95%CI 0.76-0.88)。阿片类激动剂治疗、当前流感疫苗接种和稳定住房与至少两剂接种相关;年龄≥40岁和慢性健康状况与至少三剂接种相关。作者认为居住不稳定的注射吸毒者是需要支持以提高接种率的亚人群。

要点

  • 84.1%至少接种一剂COVID-19疫苗,79.6%接种至少两剂,46.1%接种至少三剂。
  • 接种率低于澳大利亚一般人群,患病率比0.82(95%CI 0.76-0.88)。
  • 居住不稳定的注射吸毒者是需要支持以提高接种率的亚人群。

核心结论

  • 注射吸毒者COVID-19疫苗接种率高于基于既往疫苗可接受性研究预期的水平,但低于一般人群。
  • 居住不稳定的注射吸毒者是需支持以提高接种率的亚人群。

研究设计与样本

  • 2022年6-7月在澳大利亚首都城市调查868名定期注射药物者(66.0%男性,平均年龄45.6岁),自我报告COVID-19疫苗接种剂次及接种动机或障碍。
  • 将接种率与澳大利亚人群估计值比较,并使用逻辑回归识别与≥2剂和≥3剂接种相关的因素。

主要发现

  • 84.1%(n=730)至少接种一剂COVID-19疫苗,79.6%(n=691)接种≥2剂,46.1%(n=400)接种≥3剂。
  • 参与者接种可能性低于澳大利亚一般人群(患病率比0.82,95%CI 0.76-0.88)。
  • 接种主要动机是保护自己或他人免受COVID-19,障碍涉及对疫苗或政府的不信任。
  • 阿片类激动剂治疗(aOR 2.49,95%CI 1.44-4.42)、当前季节性流感疫苗接种(aOR 6.76,95%CI 3.18-16.75)和稳定住房(aOR 1.58,95%CI 1.02-2.80)与至少两剂接种相关。
  • 年龄≥40岁(对比<40岁;aOR 1.66,95%CI 1.10-2.53)或报告慢性健康状况(aOR 1.71,95%CI 1.18-2.47)与至少三剂接种几率较高相关。

关键数值与推荐

  • 至少一剂接种率84.1%(n=730),至少两剂79.6%(n=691),至少三剂46.1%(n=400)。
  • 与一般人群比较患病率比0.82(95%CI 0.76-0.88)。
  • 阿片类激动剂治疗aOR 2.49(95%CI 1.44-4.42),当前流感疫苗接种aOR 6.76(95%CI 3.18-16.75),稳定住房aOR 1.58(95%CI 1.02-2.80)。
  • 年龄≥40岁aOR 1.66(95%CI 1.10-2.53),慢性健康状况aOR 1.71(95%CI 1.18-2.47)。

临床怎么用

  • 作者认为居住不稳定的注射吸毒者是需要支持以提高疫苗接率的亚人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have reported high COVID-19 vaccine hesitancy among people who inject drugs. We aimed to examine COVID-19 vaccine coverage, motivations and barriers to vaccination, and factors associated with uptake among this population in Australia, 1.5 years after vaccine rollout commenced. METHODS: In June-July 2022, 868 people (66.0 % male, mean age 45.6 years) who regularly inject drugs and reside in an Australian capital city reported the number of COVID-19 vaccine doses they had received and their primary motivation (if vaccinated) or barrier (if unvaccinated) to receive the vaccine. We compared vaccine uptake to Australian population estimates and used logistic regression to identify factors associated with ≥ 2 dose and ≥ 3 dose uptake. RESULTS: Overall, 84.1 % (n = 730) had received at least one COVID-19 vaccine dose, 79.6 % (n = 691) had received ≥ 2 doses, and 46.1 % (n = 400) had received ≥ 3 doses. Participants were less likely to be vaccinated than the Australian general population (prevalence ratio: 0.82, 95 % confidence interval [CI]: 0.76-0.88). Key motivations to receive the vaccine were to protect oneself or others from COVID-19, while barriers pertained to vaccine or government distrust. Opioid agonist treatment (adjusted odds ratio [aOR]: 2.49, 95 % CI: 1.44-4.42), current seasonal influenza vaccine uptake (aOR: 6.76, 95 % CI: 3.18-16.75), and stable housing (aOR: 1.58, 95 % CI: 1.02-2.80) were associated with receipt of at least two vaccine doses. Participants aged ≥ 40 years (versus < 40 years; aOR: 1.66, 95 % CI: 1.10-2.53) or who reported a chronic health condition (aOR: 1.71, 95 % CI: 1.18-2.47) had higher odds of receiving at least three vaccine doses. CONCLUSION: We observed higher COVID-19 vaccine uptake than expected given previous studies of vaccine acceptability among people who inject drugs. However, it was lower than the general population. People who inject drugs and reside in unstable housing are a subpopulation that require support to increase vaccine uptake.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Price O, Dietze P, Maher L, et al. High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs. Vaccine. 2024. PMID: 38519346. doi:10.1016/j.vaccine.2024.03.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。